CHO Plus, a biotechnology firm specializing in high-productivity Chinese hamster ovary cell lines for monoclonal antibody production, secured up to $10.4 million through a BARDA project agreement to develop filovirus-targeted antibodies. The company also partnered with Avid Bioservices to scale production. Recently selected for the 2025 BioTools Innovator Accelerator, CHO Plus will receive mentorship and funding to accelerate its commercialization efforts. This dual engagement underscores growing interest in advanced cell line technologies for biologics manufacturing in the biodefense space.